Coca-Cola, Eli Lilly, & Becton Dickinson 5-2-25
episodeTranscript
jump: find in transcriptTranscript
Transcript generated automatically by AI and may contain errors.
This is Scott Becker with the Becker Private Equity and Business Podcast. Today's discussion is Coca-Cola, Eli Lilly, and Becton Dickinson. So here's what's going on with these three. Coca-Cola, which has seemingly been outperforming Pepsi, took it on the absolute chin yesterday and dropped 12%. It's now down 6% year-to-date or 5% year-to-date. The company Coca-Cola is a Berkshire Hathaway total staple. Second, Eli Lilly, which seems to have been forever on a tear the last couple of years, was down almost 12% yesterday. His Novo Neurodisk caught a key deal with CVS to have their GLP-1 be listed as the core drug on the formulary for CVS. Finally, Becton Dickinson, the medical device company, fell 18% yesterday, has released solid earnings, but it projected reduced guidance for the year. So even though it had a great quarter, it projected softer guidance for the year, and the stock literally tanked 18%. So that was a big negative for Becton Dickinson yesterday. So that's, again... Coca-Cola down 12%. Eli Lilly down almost 12%.
And Beckton Dixon down 18% yesterday. A lot of moves out there. Thank you for listening to the Becker Private Equity and Business Podcast. Thank you very, very much.
No segments match your search.
Select any passage to copy it with its citation or turn it into a shareable card.
More from Becker Private Equity & Business Podcast
We’re a Lot Closer to Being a Decent Golfer Than We Used to Be 8-2-25
NVIDIA, Microsoft, & Apple 8-1-25
7 Business News Stories We Are Following Today 8-1-25
The Markets, Microsoft, & Meta Platforms All Surging 7-31-25
A Sucker is Born Every Minute: The U.S. Putter Market 7-31-25
Empathy Matters 7-31-25